Overview of Dr. Lukin
Dr. Dana Lukin is a gastroenterologist in New York, NY and is affiliated with multiple hospitals in the area, including New York-Presbyterian Hospital, New York-Presbyterian Hospital, NewYork-Presbyterian/Columbia University Irving Medical Center, and NewYork-Presbyterian/Lower Manhattan Hospital. He received his medical degree from Icahn School of Medicine at Mount Sinai and has been in practice 9 years. He is one of 302 doctors at New York-Presbyterian Hospital and one of 41 doctors at NewYork-Presbyterian/Lower Manhattan Hospital who specialize in Gastroenterology. He also speaks multiple languages, including Spanish. He has more than 60 publications and over 500 citings.
Office
1283 York Avenue
9th Floor
New York, NY 10065
Education & Training
- New York Presbyterian Hospital (Cornell Campus)Fellowship, Gastroenterology, 2010 - 2013
- Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Internal Medicine, 2007 - 2010
- Icahn School of Medicine at Mount SinaiClass of 2007, MD, PhD
Certifications & Licensure
- NY State Medical License 2008 - 2025
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Gastroenterology
Clinical Trials
- The Impact of Time Restricted Feeding in Crohn's Disease Start of enrollment: 2021 Jan 14
- Education Intervention on Vaccination Adherence Among Inflammatory Bowel Disease (IBD) Patients Start of enrollment: 2021 Feb 04
Publications & Presentations
PubMed
- 56 citationsRetrospective Analysis of Safety of Vedolizumab in Patients With Inflammatory Bowel Diseases.Joseph Meserve, Satimai Aniwan, Jenna L. Koliani-Pace, Preeti Shashi, A Weiss
Clinical Gastroenterology and Hepatology. 2019-07-01 - 43 citationsComparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease.Matthew Bohm, Ronghui Xu, Yiran Zhang, Sashidhar Varma, Monika Fischer
Alimentary Pharmacology & Therapeutics. 2020-08-01 - 53 citationsVedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium.Neeraj Narula, Farhad Peerani, Joseph Meserve, Gursimran Kochhar, Khadija Chaudrey
The American Journal of Gastroenterology. 2018-09-01
Journal Articles
- Correction: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY ConsortiumLeah Katta, Robert Hirten, Shannon Chang, Dana Lukin, Edward V Loftus, David Faleck, Arun Swaminath, William J Sandborn, Sashidhar Varma Sagi, Sunanda Kane, Prianka Ch..., Nature
- Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY ConsortiumGursimran Kochhar, Justin Hartke, Sashidhar Varma Sagi, Edward V Loftus, Joseph Meserve, Robert Hirten, David Faleck, Shannon Chang, Dana Lukin, Farhad Peerani, Leah K..., Nature
Press Mentions
- Inpatient Monitoring May Extend Hospital Stays in Acute Severe Ulcerative ColitisJuly 30th, 2024
- Upadacitinib Induction Provided Fast Symptom Relief in Ulcerative ColitisDecember 2nd, 2022
- Higher Risk for Treatment Failure with Vedolizumab in Older IBD PatientsSeptember 30th, 2022
- Join now to see all
Professional Memberships
- Member
- Member
Other Languages
- Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: